Animal health company Elanco (NYSE: ELAN) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 10.4% year on year to $1.14 billion. Guidance for next quarter’s revenue was better than expected at $1.10 billion at the midpoint, 1.9% above analysts’ estimates. Its non-GAAP profit of $0.19 per share was 43.9% above analysts’ consensus estimates.

Is now the time to buy ELAN? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Elanco's third quarter performance was marked by strong revenue growth across both pet and farm animal segments, with management highlighting U.S. Farm Animal up 20% and solid momentum in U.S. pet health. CEO Jeffrey Simmons attributed the results to the company’s expanding innovation portfolio, particularly new products like Credelio Quattro and Zenrelia. Despite these achievements and operational improvements, the market responded negatively, reflecting ongoing concerns about margin sustainability and competitive pressures. CFO Bob VanHimbergen noted that increased investments in global pet health launches contributed to operating expense growth, though these were partially offset by productivity gains and deleveraging efforts.

Looking forward, Elanco’s guidance is underpinned by continued expansion of its innovation pipeline and expectations for further geographic rollout of key products. Management emphasized that additional revenue and margin gains are expected from the scaling of Credelio Quattro and Zenrelia internationally, as well as from operational efficiencies tied to the Elanco Ascend initiative. Simmons stated, “We see significant runway for this blockbuster and the benefits of its portfolio synergies,” while cautioning that macroeconomic dynamics and competitive launches remain watchpoints. The company is also focused on managing tariff impacts and expects to leverage its diversified product base to insulate against industry headwinds.

Key Insights from Management’s Remarks

Elanco’s leadership cited strong innovation-driven growth, portfolio breadth, and proactive operational execution as key factors shaping the quarter and the updated outlook.

• Innovation basket momentum: Management emphasized that innovation products, including Credelio Quattro and Zenrelia, accounted for much of the growth and stability across geographies and species. The innovation basket’s year-to-date revenue exceeded $655 million, and guidance for the full year was raised by $100 million.
• Rapid adoption of Credelio Quattro: Credelio Quattro became Elanco’s fastest pet health blockbuster, reaching $100 million in net sales in under eight months and capturing significant share in the U.S. broad spectrum endecto market. Management highlighted its differentiation in efficacy and palatability as drivers of adoption.
• Zenrelia’s global traction: Zenrelia continued to gain market share in the dermatology category, with robust launches in the U.S. and internationally. The product’s label update in the U.S. removed restrictive language, boosting veterinarian and pet owner confidence, and management is seeking further label alignment with international markets.
• Farm animal segment resilience: The U.S. farm animal business posted strong gains, led by Experior and poultry vaccines. Management noted that producer economics and a historically small cattle herd are supporting “sticky demand,” though they acknowledged that some revenue was pulled forward from the previous quarter due to pretariff buying in China.
• Operational and financial discipline: The company continued to focus on debt reduction, achieving a net leverage ratio of 3.7x, and refinanced its term loan to extend maturities and lower costs. Management cited the Elanco Ascend efficiency program as a key margin enhancement driver for 2026 and beyond.

Drivers of Future Performance

Management expects continued momentum from new product launches, margin improvement initiatives, and geographic expansion to shape results in the coming quarters.

• International product rollouts: Elanco plans to expand Credelio Quattro and Zenrelia into new markets in 2026, which management believes will drive further revenue growth and help offset potential declines in mature segments. Early signs from Europe and Asia indicate strong initial adoption.
• Margin enhancement through Elanco Ascend: The company is set to implement its company-wide Elanco Ascend initiative, targeting general and administrative cost savings, manufacturing efficiencies, and broader digital and automation capabilities. Management expects these efforts to support EBITDA margin expansion beginning in 2026.
• Competitive and macro pressures: While management is optimistic about share gains in core markets, they acknowledged risks from new competitive entries in parasiticides and dermatology, as well as ongoing tariff and macroeconomic headwinds. The company’s guidance incorporates these factors, and leadership emphasized proactive mitigation strategies.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will focus on (1) the global rollout and adoption rates of Credelio Quattro and Zenrelia, (2) the effectiveness and financial impact of the Elanco Ascend margin improvement program, and (3) signs that Elanco can maintain or expand market share despite competitive launches in parasiticides and dermatology. Progress in deleveraging and execution of the company’s innovation pipeline will also be closely watched.

Elanco currently trades at $21.72, down from $22.50 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free for active Edge members).

Now Could Be The Perfect Time To Invest In These Stocks

Fresh US-China trade tensions just tanked stocks—but strong bank earnings are fueling a sharp rebound. Don’t miss the bounce.

Don’t let fear keep you from great opportunities and take a look at Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.